- Patent Title: IL-21 (heterodimeric Fc-fused IL-21) fused to immunoglobulin heavy chain constant region heterodimer (heterodimeric Fc), and pharmaceutical composition comprising same
-
Application No.: US17015875Application Date: 2020-09-09
-
Publication No.: US11459367B2Publication Date: 2022-10-04
- Inventor: Kyung-Mi Lee , Seon Ah Lim , Yong Sung Kim , Ye Jin Kim
- Applicant: Korea University Research and Business Foundation , AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
- Applicant Address: KR Seoul; KR Suwon-si
- Assignee: Korea University Research and Business Foundation,AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
- Current Assignee: Korea University Research and Business Foundation,AJOU UNIVERSITY INDUSTRY-ACADEMIC COOPERATION FOUNDATION
- Current Assignee Address: KR Seoul; KR Suwon-si
- Agency: Sughrue Mion, PLLC
- Priority: KR10-2016-0113452 20160902
- Main IPC: A61K38/20
- IPC: A61K38/20 ; A61K47/68 ; C07K14/54 ; A61K45/06 ; A61P35/00 ; A61K35/17

Abstract:
A heterodimeric Fc-fused protein and a pharmaceutical composition comprising the heterodimeric Fc-fused protein are disclosed. The heterodimeric Fc-fused protein includes first and second Fc regions of an immunoglobulin heavy chain constant region (Fc) pair and in which IL-21 is bound to at least one of the N-terminus or the C-terminus of the first Fc region and/or the second Fc region, wherein CH3 domains of the first Fc region and the second Fc region are mutated such that the formation of a heterodimer is promoted. When the heterodimeric Fc-fused protein is used, an in vivo half-life of IL-21 included in the heterodimeric Fc-fused protein may be significantly increased.
Information query
IPC分类: